**Supplementary Table 2 Unadjusted and covariate adjusted hazard ratios of covid-19 mortality.**

|  |  | **COVID-19 cases (16,866)**  | **Death in 30 days (921)** | **Unadjusted HR (95% CI)** | **Adjusted HR (95% CI)**a |
| --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |
| **AHT drugs** | ACEI | 1,789 (11) | 182 (20) | 2.16 (1.83 to 2.54) | 1.08 (0.90 to 1.30) |
|  | ARB | 923 (5) | 72 (8) | 1.48 (1.16 to 1.88) | 0.84 (0.65 to 1.09) |
|  | Beta-blocker | 2,228 (13) | 263 (29) | 2.75 (2.38 to 3.17) | 1.13 (0.97 to 1.33) |
|  | Calcium channel | 1,763 (10) | 149 (16) | 1.69 (1.42 to 2.01) | 0.87 (0.72 to 1.04) |
|  | Diuretics | 583 (3) | 47 (5) | 1.52 (1.14 to 2.04) | 1.00 (0.74 to 1.36) |
|  | Other AHT | 340 (2) | 30 (3) | 1.67 (1.16 to 2.40) | 0.85 (0.59 to 1.24) |
|  |  |  |  |  |  |
| **Gender** |  |  |  |  |  |
|  | Male | 6,796 (40) | 465 (50) | 1.53 (1.35 to 1.75) | 1.51 (1.32 to 1.74) |
|  | Female | 10,070 (60) | 456 (50) | Reference | Reference |
|  |  |  |  |  |  |
| **Age group (years)** |  |  |  |  |  |
|  | 0-4 | 697 (4) | 0 (0) | 0.00 (0.00 to Inf.) | 0.00 (0.00 to Inf.) |
|  | 5-14 | 641 (4) | 0 (0) | 0.00 (0.00 to Inf.) | 0.00 (0.00 to Inf.) |
|  | 15-24 | 889 (5) | 2 (0) | 0.11 (0.03 to 0.5) | 0.10 (0.02 to 0.41) |
|  | 25-34 | 1,959 (12) | 0 (0) | 0.00 (0.00 to Inf.) | 0.00 (0.00 to Inf.) |
|  | 35-44 | 2,259 (13) | 6 (1) | 0.13 (0.06 to 0.30) | 0.12 (0.05 to 0.27) |
|  | 45-54 | 2,663 (16) | 13 (1) | 0.24 (0.13 to 0.43) | 0.23 (0.12 to 0.42) |
|  | 55-64 | 2,747 (16) | 56 (6) | Reference | Reference |
|  | 65-74 | 1,701 (10) | 126 (14) | 3.74 (2.73 to 5.12) | 3.52 (2.56 to 4.85) |
|  | 75-84 | 1,662 (10) | 310 (34) | 10.23 (7.70 to 13.60) | 8.18 (6.02 to 11.10) |
|  | 85+ | 1,648 (10) | 408 (44) | 13.94 (10.54 to 18.43) | 10.74 (7.83 to 14.72) |
|  |  |  |  |  |  |
| **Period** | January | 9 (0) | 0 (0) | 0.00 (0.00 to Inf.) | 0.00 (0.00 to Inf.) |
|  | February | 110 (1) | 0 (0) | 0.00 (0.00 to Inf.) | 0.00 (0.00 to Inf.) |
|  | March | 3,141 (19) | 121 (13) | 0.51 (0.42 to 0.61) | 0.89 (0.73 to 1.08) |
|  | April | 8,201 (49) | 610 (66) | Reference | Reference |
|  | May | 4,802 (28) | 183 (20) | 0.56 (0.47 to 0.66) | 0.47 (0.40 to 0.55) |
|  | June | 603 (4) | 7 (1) | 0.30 (0.14 to 0.64) | 0.34 (0.16 to 0.72) |
|  |  |  |  |  |  |
| **BMI** | Underweight | 574 (3) | 41 (4) | 0.96 (0.69 to 1.33) | 1.11 (0.79 to 1.55) |
|  | Normal weight | 3,127 (19) | 235 (26) | Reference | Reference |
|  | Overweight | 3,296 (20) | 196 (21) | 0.78 (0.65 to 0.94) | 0.92 (0.76 to 1.12) |
|  | Obese | 4,075 (24) | 174 (19) | 0.56 (0.46 to 0.68) | 1.04 (0.84 to 1.29) |
|  | Not known | 5,794 (34) | 275 (30) | 0.62 (0.52 to 0.74) | 1.10 (0.91 to 1.34) |
|  |  |  |  |  |  |
| **Systolic blood pressure** | <110 | 1,487 (9) | 109 (12) | 1.25 (0.99 to 1.59) | 1.30 (0.99 to 1.70) |
|  | 110 - 119 | 2,345 (14) | 128 (14) | 0.92 (0.74 to 1.16) | 1.23 (0.97 to 1.56) |
|  | 120 – 129 | 3,265 (19) | 171 (19) | 0.88 (0.72 to 1.09) | 0.98 (0.79 to 1.21) |
|  | 130 – 139 | 3,068 (18) | 181 (20) | Reference | Reference |
|  | 140 – 149 | 1,875 (11) | 130 (14) | 1.19 (0.95 to 1.48) | 0.93 (0.74 to 1.17) |
|  | 150 – 159 | 634 (4) | 45 (5) | 1.23 (0.88 to 1.70) | 0.96 (0.69 to 1.34) |
|  | 160 + | 585 (3) | 46 (5) | 1.33 (0.96 to 1.84) | 0.76 (0.54 to 1.08) |
|  | Not known | 3,607 (21) | 111 (12) | 0.52 (0.41 to 0.65)  | 5.78 (0.00 to 1,954,224.00) |
|  |  |  |  |  |  |
| **Diastolic blood pressure** | <60 | 473 (3) | 83 (9) | 4.34 (3.35 to 5.61) | 1.42 (1.05 to 1.91)  |
|  | 60 – 69 | 2,326 (14) | 194 (21) | 1.95 (1.59 to 2.38) | 1.05 (0.84 to 1.31) |
|  | 70 - 79 | 4,654 (28) | 276 (30) | 1.36 (1.13 to 1.64) | 1.03 (0.85 to 1.24) |
|  | 80 – 89 | 4,368 (26) | 191 (21) | Reference | Reference |
|  | 90 – 99 | 1,152 (7) | 50 (5) | 0.99 (0.73 to 1.35) | 1.36 (0.99 to 1.87) |
|  | 100 + | 286 (2) | 16 (2) | 1.26 (0.76 to 2.10) | 1.12 (0.66 to 1.93) |
|  | Not known | 3,607 (21) | 111 (12) | 0.70 (0.55 to 0.88) | 0.29 (0.00 to 98743.17) |
|  |  |  |  |  |  |
| **Ethnic group** | White | 8,296 (49) | 396 (43) | Reference | Reference |
|  | Black | 183 (1) | 9 (1) | 1.08 (0.56 to 2.10) | 2.60 (1.33 to 5.08) |
|  | Asian | 305 (2) | 9 (1) | 0.61 (0.32 to 1.19) | 2.15 (1.10 to 4.19) |
|  | Mixed | 98 (1) | 1 (0) | 0.21 (0.03 to 1.51) | 0.70 (0.10 to 5.05) |
|  | Other | 246 (1) | 5 (1) | 0.41 (0.17 to 1.00) | 1.04 (0.43 to 2.52) |
|  | Not known | 7,738 (46) | 501 (54) | 1.36 (1.19 to 1.55) | 1.05 (0.92 to 1.20) |
|  |  |  |  |  |  |
| **Smoking status** | Non-smoker | 10,579 (63) | 550 (60) | Reference | Reference |
|  | Smoker | 3,512 (21) | 304 (33) | 1.70 (1.48 to 1.96) | 1.12 (0.96 to 1.30) |
|  | Ex-smoker | 2,775 (16) | 67 (7) | 0.47 (0.36 to 0.60) | 0.81 (0.62 to 1.05) |
|  |  |  |  |  |  |
| **Frailty level** | Fit | 10,029 (59) | 182 (20) | Reference | Reference |
|  | Mild | 3,984 (24) | 265 (29) | 3.77 (3.12 to 4.55) | 0.91 (0.74 to 1.12) |
|  | Moderate | 1,865 (11) | 283 (31) | 9.04 (7.50 to 10.89) | 1.15 (0.91 to 1.45) |
|  | Severe | 988 (6) | 191 (21) | 12.01 (9.80 to 14.71) | 1.16 (0.88 to 1.52) |
|  |  |  |  |  |  |
| **Comorbidities** | Chronic pulmonary disease | 3,921 (23) | 156 (17) | 0.67 (0.56 to 0.80) | 0.77 (0.64 to 0.92)  |
|  | Myocardial infarction | 590 (3) | 99 (11) | 3.54 (2.87 to 4.36) | 0.98 (0.78 to 1.23) |
|  | Peripheral vascular disease | 350 (2) | 63 (7) | 3.77 (2.92 to 4.86) | 1.19 (0.91 v 1.55) |
|  | Rheumatological disease | 478 (3) | 63 (7) | 2.60 (2.01 to 3.36) | 1.09 (0.84 to 1.42) |
|  | Diabetes | 2,178 (13) | 258 (28) | 2.72 (2.36 to 3.14)  | 1.35 (1.15 to 1.58) |
|  | Metastatic tumour | 51 (0) | 12 (1) | 4.52 (2.56 to 8.00) | 2.04 (1.12 to 3.71) |
|  | Congestive heart disease | 523 (3) | 99 (11) | 4.09 (3.32 to 5.04) | 1.02 (0.81 to 1.28) |
|  | Renal disease | 1,299 (8) | 217 (24) | 4.02 (3.45 to 4.68) | 0.99 (0.84 to 1.17) |
|  | Peptic ulcer disease | 538 (3) | 70 (8) | 2.62 (2.05 to 3.34) | 0.97 (0.76 to 1.25) |
|  | Cerebrovascular disease | 909 (5) | 148 (16) | 3.60 (3.02 to 4.29) | 0.97 (0.81 to 1.17) |
|  | Cancer | 1,139 (7) | 138 (15) | 2.51 (2.10 to 3.01) | 0.90 (0.74 to 1.09) |
|  | Dementia | 980 (6) | 292 (32) | 8.65 (7.53 to 9.94) | 1.82 (1.55 to 2.12)  |
|  | Mild liver disease | 115 (1) | 16 (2) | 2.68 (1.63 to 4.39) | 1.89 (1.10 to 3.26) |
|  | Hemiplegia | 58 (0) | 3 (0) | 0.98 (0.32 to 3.05) | 0.54 (0.17 to 1.69) |
|  | Moderate liver disease | 30 (0) | 3 (0) | 1.87 (0.60 to 5.80) | 0.83 (0.24 to 2.91) |
|  |  |  |  |  |  |

HR, hazard ratio; 95% CI, 95% confidence interval; ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers
aall odds ratios were adjusted for each of the variables shown and body mass index category and comorbidities contributing to the Charlson index, as well as age group, gender, general practice and month of diagnosis.